Target and Agent Prioritization for the Children’s Oncology Group—National Cancer Institute Pediatric MATCH Trial
暂无分享,去创建一个
M. Lim | P. Adamson | T. Laetsch | Y. Cho | K. Janeway | C. Allen | N. Seibel | R. Mody | M. Irwin | D. W. Parsons | Nita L. Seibel | Carl E. Allen | Theodore W. Laetsch | Meredith S. Irwin | Megan S. Lim | Peter C. Adamson | D. Williams Parsons | Y. Jae Cho | N. L. Seibel
[1] P. Stephens,et al. Abstract LB-178: Genomic profiling of 1239 diverse pediatric cancers identifies novel discoveries across tumors , 2016 .
[2] R. Gray,et al. Abstract CT101: NCI-molecular analysis for therapy choice (NCI-MATCH) clinical trial: interim analysis , 2016 .
[3] G. Shapiro,et al. Targeting CDK4 and CDK6: From Discovery to Therapy. , 2016, Cancer discovery.
[4] Dara L Aisner,et al. An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101. , 2015, Cancer discovery.
[5] Nicolas Servant,et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. , 2015, The Lancet. Oncology.
[6] P. Sonneveld,et al. Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation , 2015, European journal of haematology.
[7] Nallasivam Palanisamy,et al. Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth. , 2015, JAMA.
[8] G. Leverger,et al. Vemurafenib Use in an Infant for High-Risk Langerhans Cell Histiocytosis. , 2015, JAMA oncology.
[9] J. Blay,et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. , 2015, The New England journal of medicine.
[10] P. Jänne,et al. Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2. , 2015, Cancer research.
[11] Gudrun Schleiermacher,et al. Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations , 2015, Nature Genetics.
[12] C. Boshoff,et al. Molecular Pathways: Targeting the Cyclin D–CDK4/6 Axis for Cancer Treatment , 2015, Clinical Cancer Research.
[13] S. Hewitt,et al. CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma , 2015, Clinical Cancer Research.
[14] P. Grenier,et al. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] M. Merad,et al. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups , 2015, The Journal of experimental medicine.
[16] F. Couch,et al. BRCA1 Circos: a visualisation resource for functional analysis of missense variants , 2015, Journal of Medical Genetics.
[17] L. Cascione,et al. The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs , 2015, Clinical Cancer Research.
[18] A. Iavarone,et al. Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma , 2015, Clinical Cancer Research.
[19] S. Keir,et al. Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673 , 2015, Pediatric blood & cancer.
[20] P. Poulikakos,et al. Targeting RAS–ERK signalling in cancer: promises and challenges , 2014, Nature Reviews Drug Discovery.
[21] L. Garraway,et al. ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors. , 2014, Cancer research.
[22] J. Utikal,et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. , 2014, The New England journal of medicine.
[23] Ravi Radhakrishnan,et al. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. , 2014, Cancer cell.
[24] D. Muzny,et al. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. , 2014, Blood.
[25] C. Wahlestedt,et al. The BET Bromodomain Inhibitor I-BET151 Acts Downstream of Smoothened Protein to Abrogate the Growth of Hedgehog Protein-driven Cancers* , 2014, The Journal of Biological Chemistry.
[26] Adam Kiezun,et al. Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma , 2014, Proceedings of the National Academy of Sciences.
[27] Li Ding,et al. The Genomic Landscape of Childhood and Adolescent Melanoma , 2014, The Journal of investigative dermatology.
[28] Narasimhan P. Agaram,et al. Recurrent MYOD1 mutations in pediatric and adult sclerosing and spindle cell rhabdomyosarcomas: Evidence for a common pathogenesis , 2014, Genes, chromosomes & cancer.
[29] A. Adjei,et al. The clinical development of MEK inhibitors , 2014, Nature Reviews Clinical Oncology.
[30] B. Pan,et al. FGFR2 Is Amplified in the NCI-H716 Colorectal Cancer Cell Line and Is Required for Growth and Survival , 2014, PloS one.
[31] G. Linette,et al. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. , 2014, JAMA.
[32] R. Beroukhim,et al. Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition , 2014, Nature Medicine.
[33] B. Korf,et al. The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[34] C. Antonescu,et al. NSD3-NUT fusion oncoprotein in NUT midline carcinoma: implications for a novel oncogenic mechanism. , 2014, Cancer discovery.
[35] P. Stephens,et al. Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions. , 2014, Cancer discovery.
[36] James R. Anderson,et al. Risk-based treatment for nonrhabdomyosarcoma soft tissue sarcomas (NRSTS) in patients under 30 years of age: Children’s Oncology Group study ARST0332. , 2014 .
[37] James R. Anderson,et al. Randomized phase II trial of bevacizumab and temsirolimus in combination with vinorelbine (V) and cyclophosphamide (C) for first relapse/disease progression of rhabdomyosarcoma (RMS): A report from the Children's Oncology Group (COG). , 2014 .
[38] B. Taylor,et al. Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. , 2014, Cancer research.
[39] S. Gabriel,et al. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. , 2014, Cancer discovery.
[40] S. Gabriel,et al. Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.
[41] R. Beroukhim,et al. BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma , 2013, Clinical Cancer Research.
[42] J. Utikal,et al. Neoadjuvant Imatinib in Advanced Primary or Locally Recurrent Dermatofibrosarcoma Protuberans: A Multicenter Phase II DeCOG Trial with Long-term Follow-up , 2013, Clinical Cancer Research.
[43] F. Speleman,et al. BET bromodomain protein inhibition is a therapeutic option for medulloblastoma , 2013, Oncotarget.
[44] Barbara S. Paugh,et al. Novel oncogenic PDGFRA mutations in pediatric high-grade gliomas. , 2013, Cancer research.
[45] L. Garraway,et al. Oncogenic and drug sensitive NTRK1 rearrangements in lung cancer , 2013, Nature Medicine.
[46] T. Curran,et al. Phase I Study of Vismodegib in Children with Recurrent or Refractory Medulloblastoma: A Pediatric Brain Tumor Consortium Study , 2013, Clinical Cancer Research.
[47] Andrew C. Wood,et al. Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma , 2013, Clinical Cancer Research.
[48] S. Fulda,et al. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma. , 2013, Cancer letters.
[49] C. Mullighan,et al. Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] G. Ganji,et al. BET Inhibition Silences Expression of MYCN and BCL2 and Induces Cytotoxicity in Neuroblastoma Tumor Models , 2013, PloS one.
[51] Khin Thway,et al. Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth In Vitro and In Vivo , 2013, Clinical Cancer Research.
[52] Michael Thomas,et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. , 2013, The New England journal of medicine.
[53] Jan Bogaerts,et al. Designing transformative clinical trials in the cancer genome era. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] Thomas Bachelot,et al. Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer , 2013, Clinical Cancer Research.
[55] J. Maris,et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. , 2013, The Lancet. Oncology.
[56] Richard Simon,et al. Implementing personalized cancer genomics in clinical trials , 2013, Nature Reviews Drug Discovery.
[57] K. Stegmaier,et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. , 2013, Cancer discovery.
[58] C. Berking,et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. , 2013, The Lancet. Oncology.
[59] G. Millington. Mutations of the BRAF gene in human cancer, by Davies et al. (Nature 2002; 417: 949–54) , 2013, Clinical and experimental dermatology.
[60] Reid C Thompson,et al. Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma , 2013, Clinical Cancer Research.
[61] E. Thiele,et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial , 2013, The Lancet.
[62] G. Page,et al. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. , 2013, The Journal of clinical investigation.
[63] K. Flaherty,et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.
[64] G. Shapiro,et al. Cyclin-dependent kinase 4/6 inhibition in cancer therapy , 2012, Cell cycle.
[65] B. Weigelt,et al. Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer , 2012, Front. Oncol..
[66] J. Utikal,et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. , 2012, The New England journal of medicine.
[67] Jill P. Mesirov,et al. MEDULLOBLASTOMA EXOME SEQUENCING UNCOVERS SUBTYPE-SPECIFIC SOMATIC MUTATIONS , 2012, Nature.
[68] R. Pieper,et al. Sensitivity of glioblastomas to clinically available MEK inhibitors is defined by neurofibromin 1 deficiency. , 2012, Cancer research.
[69] J. Sarkaria,et al. p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells. , 2012, Neuro-oncology.
[70] Dirk Schadendorf,et al. Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group , 2012 .
[71] Kris Chang,et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. , 2012, The New England journal of medicine.
[72] R. Kurzrock,et al. KRASness and PIK3CAness in Patients with Advanced Colorectal Cancer: Outcome after Treatment with Early-Phase Trials with Targeted Pathway Inhibitors , 2012, PloS one.
[73] N. Gray,et al. Functional characterization of an isoform-selective inhibitor of PI3K-p110β as a potential anticancer agent. , 2012, Cancer discovery.
[74] L. Macconaill,et al. Critical oncogenic mutations in newly diagnosed pediatric diffuse intrinsic pontine glioma , 2012, Pediatric blood & cancer.
[75] Razelle Kurzrock,et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[76] Furu Wang,et al. Common BRCA1 and BRCA2 mutations in breast cancer families: a meta-analysis from systematic review , 2012, Molecular Biology Reports.
[77] P. Varlet,et al. Mesenchymal Transition and PDGFRA Amplification/Mutation Are Key Distinct Oncogenic Events in Pediatric Diffuse Intrinsic Pontine Gliomas , 2012, PloS one.
[78] Yu Shyr,et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. , 2012, The New England journal of medicine.
[79] A. Iafrate,et al. Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers , 2012, Science Translational Medicine.
[80] C. French. Pathogenesis of NUT midline carcinoma. , 2012, Annual review of pathology.
[81] L. Borsu,et al. Oncogene Mutation Profiling of Pediatric Solid Tumors Reveals Significant Subsets of Embryonal Rhabdomyosarcoma and Neuroblastoma with Mutated Genes in Growth Signaling Pathways , 2011, Clinical Cancer Research.
[82] A. Godwin,et al. Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study. , 2011, Gynecologic oncology.
[83] P. Sandy,et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains , 2011, Proceedings of the National Academy of Sciences.
[84] P. Houghton,et al. Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression. , 2011, Biochemical and biophysical research communications.
[85] D. Bodurka,et al. A Phase I Trial of Liposomal Doxorubicin, Bevacizumab, and Temsirolimus in Patients with Advanced Gynecologic and Breast Malignancies , 2011, Clinical Cancer Research.
[86] B. Weigelt,et al. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs , 2011, Oncogene.
[87] X. Chen,et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.
[88] A. Hauschild,et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.
[89] Miyuki Yoshida,et al. The Selective Class I PI3K Inhibitor CH5132799 Targets Human Cancers Harboring Oncogenic PIK3CA Mutations , 2011, Clinical Cancer Research.
[90] A. von Deimling,et al. Prognostic but not predictive role of platelet‐derived growth factor receptors in patients with recurrent glioblastoma , 2011, International journal of cancer.
[91] M. Ellis,et al. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer , 2011, Breast Cancer Research.
[92] C. Pui,et al. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[93] Razelle Kurzrock,et al. PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors , 2011, Molecular Cancer Therapeutics.
[94] S. Dacic,et al. Phase II Study of Everolimus (RAD001) in Previously Treated Small Cell Lung Cancer , 2010, Clinical Cancer Research.
[95] Jeffrey W. Clark,et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.
[96] William B. Smith,et al. Selective inhibition of BET bromodomains , 2010, Nature.
[97] W. Hahn,et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. , 2010, Blood.
[98] Kam Y. J. Zhang,et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma , 2010, Nature.
[99] Francesca Molinari,et al. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. , 2010, The Journal of clinical investigation.
[100] E. Knudsen,et al. Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure , 2010, Oncogene.
[101] Yonghong Xiao,et al. Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM , 2010, Proceedings of the National Academy of Sciences.
[102] M. Belvin,et al. Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3′ Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models , 2010, Clinical Cancer Research.
[103] M. Prados,et al. Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. , 2010, Cancer research.
[104] C. Hawkins,et al. Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[105] Eugene A. Mash,et al. Molecular Pharmacology and Antitumor Activity of PHT-427, a Novel Akt/Phosphatidylinositide-Dependent Protein Kinase 1 Pleckstrin Homology Domain Inhibitor , 2010, Molecular Cancer Therapeutics.
[106] M. Belvin,et al. Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors. , 2010, Cancer research.
[107] M. O’Connor,et al. ATM Deficiency Sensitizes Mantle Cell Lymphoma Cells to Poly(ADP-Ribose) Polymerase-1 Inhibitors , 2010, Molecular Cancer Therapeutics.
[108] H. Lane,et al. Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells , 2009, Proceedings of the National Academy of Sciences.
[109] L. Staudt,et al. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. , 2009, The Journal of clinical investigation.
[110] Kevin Curran,et al. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. , 2009, Cancer research.
[111] Jingwu Xie,et al. MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas , 2009, Cell cycle.
[112] D. Sabatini,et al. An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1* , 2009, Journal of Biological Chemistry.
[113] G. Bossi,et al. MEK/ERK inhibitor U0126 affects in vitro and in vivo growth of embryonal rhabdomyosarcoma , 2009, Molecular Cancer Therapeutics.
[114] John M. Maris,et al. Identification of ALK as a major familial neuroblastoma predisposition gene , 2008, Nature.
[115] Gudrun Schleiermacher,et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma , 2008, Nature.
[116] Denis Lacombe,et al. Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[117] J. Baselga,et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. , 2008, Cancer research.
[118] Alice T. Loo,et al. PTEN-deficient cancers depend on PIK3CB , 2008, Proceedings of the National Academy of Sciences.
[119] M. Jeschke. Faculty Opinions recommendation of Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. , 2008 .
[120] Hans E. Huber,et al. Breast Tumor Cells with PI3K Mutation or HER2 Amplification Are Selectively Addicted to Akt Signaling , 2008, PloS one.
[121] Li Ding,et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. , 2008, Cancer research.
[122] M. Loda,et al. Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesis , 2008, Nature.
[123] R. Lackman,et al. Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy , 2008, Modern Pathology.
[124] L. Toral-Barza,et al. Response and determinants of cancer cell susceptibility to PI3K inhibitors: Combined targeting of PI3K and Mek1 as an effective anticancer strategy , 2008, Cancer biology & therapy.
[125] S. Signoretti,et al. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. , 2007, Clinical genitourinary cancer.
[126] R. Porcher,et al. Imatinib Mesylate as a Preoperative Therapy in Dermatofibrosarcoma: Results of a Multicenter Phase II Study on 25 Patients , 2007, Clinical Cancer Research.
[127] Ji Luo,et al. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism , 2006, Nature Reviews Genetics.
[128] P. Houghton,et al. Pharmacologic inhibition of cyclin-dependent kinase 4/6 activity arrests proliferation in myoblasts and rhabdomyosarcoma-derived cells , 2006, Molecular Cancer Therapeutics.
[129] B. Scheithauer,et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[130] John D. Minna,et al. Activating Mutations of the Noonan Syndrome-Associated SHP2/PTPN11 Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia , 2004, Cancer Research.
[131] A. D. Van den Abbeele,et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[132] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[133] A. Bale,et al. The hedgehog pathway and basal cell carcinomas. , 2001, Human molecular genetics.
[134] H. Zou,et al. A Phase I Pharmacologic Study of Necitumumab (imc-11f8), a Fully Human Igg1 Monoclonal Antibody the Alk/ros1 Inhibitor Pf-06463922 Overcomes Primary Resistance to Crizotinib in Alk-driven Neuroblastoma , 2022 .
[135] R. Doebele,et al. TRKing down an old oncogene in a new era of targeted therapy. , 2015, Cancer discovery.
[136] Lisa McShane,et al. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network. , 2014, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[137] Lucio Crinò,et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. , 2013, The Lancet. Oncology.
[138] J. Lee,et al. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. , 2013, Cancer research.
[139] C. Pratilas,et al. Targeting oncogenic BRAF in human cancer. , 2012, Current topics in microbiology and immunology.
[140] J. Blay,et al. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[141] Lisa L. Smith,et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. , 2010, Cancer research.